文献速递脊柱关节炎

古塞奇尤单抗在活动性银屑病关节炎患者中通过复合指数提供持续的结构域特异性和全面疗效

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究汇总了DISCOVER-1(n=381)和DISCOVER-2(n=739)两项3期试验数据,评估古塞奇尤单抗治疗活动性银屑病关节炎的复合指数疗效。结果显示,与安慰剂相比,古塞奇尤单抗在多个复合指数上均取得更高应答率,且疗效持续至第52周。

要点

  • 第24周时,古塞奇尤单抗组在DAPSA低疾病活动度和缓解、PASDAS低疾病活动度和极低疾病活动度、MDA及VLDA的应答率均高于安慰剂组(所有未校正P<0.05)。
  • 第52周时,古塞奇尤单抗每4周组和每8周组的DAPSA低疾病活动度应答率分别为54.2%和52.5%,DAPSA缓解率分别为18.2%和17.6%。
  • 安慰剂交叉至古塞奇尤单抗组在换药后所有复合指数应答率从第24周至第52周均有所增加。

核心结论

  • 古塞奇尤单抗治疗在1年内为银屑病关节炎的多个结构域提供了稳健且持续的获益,表明其是治疗银屑病关节炎多种表现的有效疗法。

研究设计与样本

  • 汇总了3期DISCOVER-1(n=381)和DISCOVER-2(n=739)研究的数据。
  • 两项研究中患者按1:1:1随机分配至皮下古塞奇尤单抗100 mg每4周、古塞奇尤单抗100 mg第0周和第4周后每8周、或安慰剂每4周并在第24周交叉至古塞奇尤单抗100 mg每4周。
  • 通过第24周应用治疗失败规则,通过第52周对缺失数据采用无应答者填补。

主要发现

  • 第24周时,古塞奇尤单抗组达到DAPSA低疾病活动度和缓解、PASDAS低疾病活动度和极低疾病活动度、MDA及VLDA的患者比例均高于安慰剂组(所有未校正P<0.05)。
  • 第52周时,古塞奇尤单抗每4周组和每8周组的DAPSA低疾病活动度应答率分别为54.2%和52.5%,DAPSA缓解率分别为18.2%和17.6%。
  • 第52周时,古塞奇尤单抗每4周组和每8周组的PASDAS低疾病活动度应答率分别为45.3%和41.9%,PASDAS极低疾病活动度应答率分别为16.9%和19.5%。
  • 第52周时,古塞奇尤单抗每4周组和每8周组的MDA应答率分别为35.9%和30.7%,VLDA应答率分别为13.1%和14.4%。
  • 安慰剂交叉至古塞奇尤单抗组在换药后所有复合指数应答率从第24周至第52周均有所增加。

关键数值与推荐

  • 第52周古塞奇尤单抗每4周组DAPSA低疾病活动度54.2%、缓解18.2%、PASDAS低疾病活动度45.3%、PASDAS极低疾病活动度16.9%、MDA 35.9%、VLDA 13.1%。
  • 第52周古塞奇尤单抗每8周组DAPSA低疾病活动度52.5%、缓解17.6%、PASDAS低疾病活动度41.9%、PASDAS极低疾病活动度19.5%、MDA 30.7%、VLDA 14.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing composite indices. METHODS: Data were pooled from the phase 3 DISCOVER-1 (n = 381) and DISCOVER-2 (n = 739) studies. In both studies, patients were randomized 1:1:1 to subcutaneous guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, then Q8W; or placebo Q4W with crossover to guselkumab 100 mg Q4W at week 24. Composite indices used to assess efficacy through week 52 included Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriatic Arthritis Disease Activity Score (PASDAS), minimal disease activity (MDA), and very low disease activity (VLDA). Through week 24, treatment failure rules were applied. Through week 52, non-responder imputation was used for missing data. RESULTS: Greater proportions of guselkumab- than placebo-treated patients achieved DAPSA low disease activity (LDA) and remission, PASDAS LDA and VLDA, MDA, and VLDA at week 24 vs placebo (all unadjusted P < 0.05). At week 52, in the guselkumab Q4W and Q8W groups, respectively, response rates were as follows: DAPSA LDA, 54.2% and 52.5%; DAPSA remission, 18.2% and 17.6%; PASDAS LDA, 45.3% and 41.9%; PASDAS VLDA, 16.9% and 19.5%; MDA, 35.9% and 30.7%; and VLDA, 13.1% and 14.4%. In the placebo-crossover-to-guselkumab group, response rates for all composite indices increased after patients switched to guselkumab, from week 24 through week 52. CONCLUSION: Treatment with guselkumab provided robust and sustained benefits across multiple PsA domains through 1 year, indicating that guselkumab is an effective therapy for the diverse manifestations of PsA. TRIAL REGISTRATION: NCT03162796; NCT03158285.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023. PMID: 35766811. doi:10.1093/rheumatology/keac375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。